Systematic review of management options for women with a hereditary predisposition to ovarian cancer

Gynecologic Oncology

Volumn 93, Issue 2, 2004, Pages 280-286

  Rosen, Barry ^a   Kwon, Janice ^b   Fung, Michael Fung Kee ^c   Gagliardi, Anna ^d   Chambers, Alexandra ^e  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d Surgical Oncology Program   (Canada)

^e CANCER CARE ONTARIO   (Canada)

Author keywords

Management; Ovarian cancer; Predisposition

Indexed keywords

CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CLINICAL TRIAL; COHORT ANALYSIS; CONSENSUS DEVELOPMENT; DATA BASE; EARLY MENOPAUSE; FEMALE; GENETIC PREDISPOSITION; HARM REDUCTION; HUMAN; LAPAROSCOPY; LIFE EXPECTANCY; LIFESPAN; META ANALYSIS; MORALITY; OVARIECTOMY; OVARY CARCINOMA; OVARY TUMOR; PATIENT CARE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; STATISTICAL SIGNIFICANCE;

EID: 1942445033     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.02.013     Document Type: Article

References (50)

1. Kerlikowske K., Brown J.S., Grady D.G. Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet. Gynecol. 80:1992;700-707.
2. Ponder B.A., Peto J., Easton D.F. Famil. ovarian cancer. 1992;Chapman & Hall, London.
3. Risch H.A., McLaughlin J.R., Cole D.E., Rosen B., Bradley L., Kwan E.et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am. J. Hum. Genet. 68:2001;700-710.
4. Ford D., Easton D.F., Stratton M., Narod S., Goldgar D., Devilee P.et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 62:1998;676-689.
5. Narod S.A., Madlensky L., Bradley L., Cole D., Tonin P., Rosen B.et al. Hereditary and familial ovarian cancer in southern Ontario. Cancer. 74:1994;2341-2346.
6. King M.C., Marks J.H., Mandell J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 302:2003;643-646.
7. Berchuck A., Schildkraut J.M., Marks J.R., Futreal P.A. Managing hereditary ovarian cancer risk. Cancer. 86:1999;2517-2524.
8. Bishop D.T. BRCA1 and BRCA2 and breast cancer incidence: a review. Ann. Oncol. 10:1999;113-119.
9. Schrag D., Kuntz K.M., Garber J.E., Weeks J.C. Decision analysis - Effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutation. N. Engl. J. Med. 336:1997;1465-1471.
10. NIH Consensus Development Panel on Ovarian Cancer Ovarian cancer. Screening, treatment, and follow-up. JAMA. 273:1995;491-497.
11. Burke W., Petersen G., Lynch P., Botkin J., Daly M., Garber J.et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer: I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA. 277:1997;915-919.
12. Vasen H.F., Haites N.E., Evans D.G., Steel C.M., Moller P., Hodgson S.et al. Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group. Eur. J. Cancer. 34:1998;1922-1926.
13. Committee on Quality Assessment American College of Obstetricians and Gynecologists Prophylactic bilateral oophorectomy to prevent epithelial carcinoma. Number 2 - December 1994. Int. J. Gynaecol. Obstet. 52:1996;101-102.
14. Eisinger F., Alby N., Bremond A., Dauplat J., Espie M., Janiaud P.et al. Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee. Ann. Oncol. 9:1998;939-950.
15. Grann V.R., Panageas K.S., Whang W., Antman K.H., Neugut A.I. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J. Clin. Oncol. 16:1998;979-985.
16. Kauff N.D., Satagopan J.M., Robson M.E., Scheuer L., Hensley M., Hudis C.A.et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 346:2002;1609-1615.
17. Struewing J.P., Watson P., Easton D.F., Ponder B.A., Lynch H.T., Tucker M.A. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J. Natl. Cancer Inst. Monogr. 17:1995;33-35.
18. Piver M.S., Baker T.R., Jishi M.F., Sandecki A.M., Tsukada Y., Natarajan N.et al. Familial ovarian cancer. A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991. Cancer. 71:1993;582-588.
19. Rebbeck T.R., Lynch H.T., Neuhausen S.L., Narod S.A., Van't Veer L., Garber J.E.et al. The Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346:2002;1616-1622.
20. van Roosmalen M.S., Verhoef L.C., Stalmeier P.F., Hoogerbrugge N., van Daal W.A. Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy. J. Clin. Oncol. 20:2002;2092-2100.
21. Elit L., Rosen B., Goel V., McLaughlin J., Fung M.F., Shime J.et al. Prophylactic oophorectomy in Ontario. Fam. Cancer. 1:2001;143-148.
22. Bateman B.G., Kolp L.A., Hoeger K. Complications of laparoscopy - Operative and diagnostic. Fertil. Steril. 66:1996;30-35.
23. Mirhashemi R., Harlow B.L., Ginsburg E.S., Signorello L.B., Berkowitz R., Feldman S. Predicting risk of complications with gynecologic laparoscopic surgery. Obstet. Gynecol. 92:1998;327-331.
24. Kritz-Silverstein D., Barrett-Connor E., Wingard D.L. Hysterectomy, oophorectomy, and heart disease risk factors in older women. Am. J. Public Health. 87:1997;676-680.
25. Colditz G.A., Willett W.C., Stampfer M.J., Rosner B., Speizer F.E., Hennekens C.H. Menopause and the risk of coronary heart disease in women. N. Engl. J. Med. 316:1987;1105-1110.
26. Aitken J.M., Hart D.M., Lindsay R. Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy. BMJ. 3:1973;515-518.
27. Nathorst-Boos J., von Schoultz B., Carlstrom K. Elective ovarian removal and estrogen replacement therapy - Effects on sexual life, psychological well-being and androgen status. J. Psychosom. Obstet. Gynaecol. 14:1993;283-293.
28. Blake J.M., Collins J.A., Reid R.L., Fedorkow D.M., Lalonde A.B. The SOGC statement on the WHI report on the estrogen and progestin use in postmenopausal women. J. Obstet. Gynaecol. Can. 24:2002;783-787.
29. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 288:2002;321-333.
30. Colgan T.J., Murphy J., Cole D.E., Narod S., Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am. J. Surg. Pathol. 25:2001;1283-1289.
31. Paley P.J., Swisher E.M., Garcia R.L., Agoff S.N., Greer B.E., Peters K.L.et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol. Oncol. 80:2001;176-180.
32. Colgan T.J., Boerner S.L., Murphy J., Cole D., Narod S., Rosen B. Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy. Gynecol. Oncol. 85:2002;397-403.
33. Schwartz P.E. The role of prophylactic oophorectomy in the avoidance of ovarian cancer. Int. J. Gynaecol. Obstet. 39:1992;175-184.
34. Meijer W.J., van Lindert A.C. Prophylactic oophorectomy. Eur. J. Obstet. Gynecol. Reprod. Biol. 47:1992;59-65.
35. Averette H.E., Nguyen H.N. The role of prophylactic oophorectomy in cancer prevention. Gynecol. Oncol. 55:1994;t-41.
36. Brose M.S., Rebbeck T.R., Calzone K.A., Stopfer J.E., Nathanson K.L., Weber B.L. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J. Natl. Cancer Inst. 94:2002;1365-1372.
37. Levine D.A., Lin O., Barakat R.R., Robson M.E., McDermott D., Cohen L.et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol. Oncol. 80:2001;395-398.
38. Goshen R., Chu W., Elit L., Pal T., Hakimi J., Ackerman I.et al. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecol. Oncol. 79:2000;477-481.
39. Lavie O., Hornreich G., Ben-Arie A., Renart G., Renbaum P., Levy-Lahad E.et al. BRCA1/2 germline mutations in women with uterine serous papillary carcinoma. [abstract] Gynecol. Oncol. 88:2003;194.
40. Hill D.J. Complications of hysterectomy. Baillieres Clin. Obstet. Gynaecol. 11:1997;181-197.
41. Harris W.J. Complications of hysterectomy. Clin. Obstet. Gynecol. 40:1997;928-938.
42. Rebbeck T.R., Levin A.M., Eisen A., Snyder C., Watson P., Cannon-Albright L.et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J. Natl. Cancer Inst. 91:1999;1475-1479.
43. Boyd J., Sonoda Y., Federici M.G., Bogomolniy F., Rhei E., Maresco D.L.et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 283:2000;2260-2265.
44. Rubin S.C., Benjamin I., Behbakht K., Takahashi H., Morgan M.A., LiVolsi V.A.et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N. Engl. J. Med. 335:1996;1413-1416.
45. Narod S.A., Risch H., Moslehi R., Dorum A., Neuhausen S., Olsson H.et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N. Engl. J. Med. 339:1998;424-428.
46. Modan B., Hartge P., Hirsh-Yechezkel G., Chetrit A., Lubin F., Beller U.et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 345:2001;235-240.
47. Hankinson S.E., Hunter D.J., Colditz G.A., Willett W.C., Stampfer M.J., Rosner B.et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA. 270:1993;2813-2818.
48. Rosenblatt K.A., Thomas D.B. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer Epidemiol. Biomarkers Prev. 5:1996;933-935.
49. Narod S.A., Sun P., Ghadirian P., Lynch H., Isaacs C., Garber J.et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet. 357:2001;1467-1470.
50. Tiller K., Meiser B., Butow P., Clifton M., Thewes B., Friedlander M.et al. Psychological impact of prophylactic oophorectomy in women at increased risk of developing ovarian cancer: a prospective study. Gynecol. Oncol. 86:2002;212-219.